We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
“None of us have experience launching in a pandemic,” Victor Bultó, Novartis’ U.S. pharma president, acknowledged ahead of last week’s FDA green light for multiple sclerosis med Kesimpta. But the company thinks it’s pretty well set up for the task.